'Refuse-To-Accept' Policy Outlined For De Novos In New US FDA Draft Guidance

Following a user fee deal that will subject de novo applications to performance goals and user-fee payments, US FDA has proposed a guidance that attempts to explain its process for considering when to accept, and when not to accept, a de novo submission for review.